Patient-Derived Xenograft Model Market to Grow with a CAGR of 9.97% through 2028
Rising interest in immunotherapy and genomic profiling is expected to
drive the Global Patient-Derived Xenograft Model Market growth in the forecast
period, 2024-2028.
According to
TechSci Research report, “Patient-Derived Xenograft Model Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2028”, the Global Patient-Derived Xenograft Model Market stood at USD 1.98
billion in 2022 and is anticipated to grow with a CAGR of 9.97% in the forecast
period, 2024-2028. The Patient-Derived Xenograft Model Market is witnessing
remarkable growth due to its pivotal role in cancer research, drug development,
and the emergence of personalized medicine. As cancer remains a significant
global health challenge, PDX models are poised to play an increasingly
important role in accelerating our understanding of the disease and developing
more effective treatments, making this market a focal point of innovation and
investment in the field of oncology. Thirdly, the pharmaceutical industry is
increasingly recognizing the benefits of PDX models in drug development. These
models serve as a critical bridge between preclinical research and clinical
trials, helping pharmaceutical companies identify promising drug candidates and
streamline the drug development process. Moreover, the continuous advancements
in PDX technology, such as the development of patient-derived organoids and
improved engraftment techniques, are enhancing the model's reliability and
expanding its applications. This, in turn, is attracting greater investments
and driving the growth of the PDX model market. PDX models are created by
transplanting tumor cells from a patient into a mouse or other animal. These
models can be used to study the biology of cancer, test new cancer drugs, and
develop personalized cancer therapies.
Advancements in PDX technology are revolutionizing cancer research and
drug development. These models offer a way to bridge the gap between
preclinical studies and clinical trials, potentially leading to more effective
cancer treatments. Pharmaceutical companies are increasingly recognizing the
value of PDX models in drug development. With improved engraftment rates and
high-throughput screening capabilities, PDX models have become a cost-effective
and reliable tool for preclinical drug testing. The shift toward personalized
medicine is driving the demand for PDX models. As healthcare providers and
pharmaceutical companies seek to tailor treatments to individual patients, the
need for PDX models that accurately represent patient-specific tumor
characteristics is on the rise. PDX models are not limited to drug development.
They are also used in basic cancer research, biomarker discovery, and the study
of cancer biology. The versatility of PDX models has broadened their appeal and
utility in the research community. The establishment of global PDX model
collaborations and biobanks has facilitated the sharing of PDX resources and
expertise among researchers and institutions worldwide. This has led to a more
efficient use of PDX models and accelerated research efforts.
Browse over XX market data Figures spread through XX Pages and an
in-depth TOC on
"Global Patient-Derived Xenograft Model Market.”
In drug development,
the ability to evaluate potential therapeutic agents in a setting that closely
mimics the human disease microenvironment is invaluable. PDX models provide
this advantage by preserving the tumor's architecture, cellular diversity, and
stromal components. Consequently, researchers can assess drug pharmacokinetics,
toxicity, and efficacy in a manner that more accurately reflects human
responses. This not only increases the likelihood of identifying successful
drug candidates but also reduces the risk of costly late-stage failures in
clinical trials. Furthermore, the advent of precision medicine has reinforced
the importance of patient-specific approaches in drug development. PDX models
play a pivotal role in this paradigm shift by enabling researchers to create
"avatar mice" that carry tumors derived from individual patients.
These avatars can be used to test a range of therapeutic options, helping
identify the most effective treatment strategies for each patient. Such
tailored approaches hold immense promise for improving patient outcomes and
reducing the often-debilitating side effects associated with conventional
treatments.
The Global Patient-Derived Xenograft Model Market is segmented into Tumor
type, type, end user, regional distribution, and company.
Based on tumor types, the Global Patient-Derived Xenograft Model Market is
segmented into Lung Cancer, Pancreatic
Cancer, Prostate Cancer, Breast Cancer, and Other Cancer. Based on the tumor types, the breast cancer
segment emerged as the dominant player in the global market for Patient-Derived
Xenograft Model in 2022.This is attributed to increasing breast cancer cases
across the world. First and foremost, breast cancer is one of the most
prevalent cancers worldwide, affecting millions of individuals each year. Its
high incidence has made it a priority for research and drug development efforts,
driving significant investments into understanding its complexities and
identifying effective treatments. PDX models have proven to be particularly
valuable in breast cancer research due to their ability to faithfully replicate
the genetic and molecular characteristics of patient tumors. Researchers can
use these models to study the heterogeneity of breast cancer subtypes and test
potential therapies tailored to individual patients. Second, the rising
interest in personalized medicine has propelled the demand for PDX models in
breast cancer research. Personalized medicine seeks to match patients with the
most effective treatments based on their genetic profiles and the specific
characteristics of their tumors.
Based on model type, the Global Patient-Derived Xenograft Model Market is
segmented into Mice, and Rats. Based on the model type, the mice model
segment emerged as the dominant player in the global market for Patient-Derived
Xenograft Model in 2022. Mice models can be used to study a wide range of tumor
types, including solid tumors and hematological malignancies. Their versatility
allows researchers to investigate various aspects of cancer biology, from tumor
initiation and progression to metastasis and treatment resistance. This
adaptability is essential in a diverse research landscape. Mice models have a
well-established infrastructure, including the availability of various strains
of immunodeficient mice that are conducive to PDX model generation.
North America emerged as the dominant player in the global
Patient-Derived Xenograft Model market in 2022, holding the largest market
share. This is on account of several key factors such as advanced healthcare
infrastructure, Strong Research and Development Ecosystem and high regulatory
acceptance. Regulatory agencies in
North America, such as the U.S. Food and Drug Administration (FDA), have
recognized the value of PDX models in drug development. Their acceptance and
willingness to consider PDX model data in regulatory submissions have
encouraged their widespread use by pharmaceutical companies and researchers.
Major companies operating in Global Patient-Derived Xenograft Model
Market are:
- Charles River
Laboratories Inc.
- The Jackson Laboratory
- Crown Bioscience,Inc.
- Altogen Labs
- Envigo
- WuxiAppTec
- Oncodesign
- Hera BioLabs
- XenTech
- Abnova Corporation
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“The global demographic shift toward an aging population is a
significant driver of Patient-Derived Xenograft Model growth. The global cancer
incidence is increasing due to a number of factors, including aging
populations, unhealthy lifestyles, and environmental pollution. This is
increasing the demand for effective cancer treatments. There are currently no
cures for many types of cancer, and existing treatments can have serious side
effects. PDX models can be used to develop new and more effective cancer
therapies that are better tolerated by patients. There are a number of new technologies being
developed to improve the efficiency and reproducibility of PDX model creation.
These technologies are expected to drive the growth of the market.” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Patient-Derived Xenograft
Model Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Tumor Type
(Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer),
By Type (Mice, Rats), By End-User (Inpatient Settings, Community Settings) By
Region and Competition ”,
has evaluated the future growth potential of Global Patient-Derived Xenograft
Model Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Patient-Derived
Xenograft Model Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com